Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $17.10 Consensus Target Price from Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have earned a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $17.10.

A number of research firms recently issued reports on ROIV. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a report on Monday, August 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Tuesday, June 18th. Finally, Piper Sandler upped their price target on Roivant Sciences from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th.

Institutional Investors Weigh In On Roivant Sciences

Institutional investors have recently made changes to their positions in the stock. Mutual of America Capital Management LLC increased its holdings in shares of Roivant Sciences by 0.4% in the 2nd quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company’s stock valued at $3,457,000 after purchasing an additional 1,142 shares in the last quarter. Acadian Asset Management LLC increased its holdings in Roivant Sciences by 23.2% in the second quarter. Acadian Asset Management LLC now owns 8,510 shares of the company’s stock valued at $89,000 after buying an additional 1,603 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Roivant Sciences during the 2nd quarter valued at approximately $34,000. Headlands Technologies LLC purchased a new stake in shares of Roivant Sciences during the 4th quarter worth approximately $36,000. Finally, DNB Asset Management AS grew its holdings in shares of Roivant Sciences by 6.4% in the 2nd quarter. DNB Asset Management AS now owns 56,022 shares of the company’s stock worth $592,000 after acquiring an additional 3,386 shares during the period. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $12.30 on Friday. The stock has a market cap of $9.09 billion, a P/E ratio of 2.43 and a beta of 1.25. Roivant Sciences has a twelve month low of $8.24 and a twelve month high of $13.24. The stock has a 50 day moving average of $11.17 and a two-hundred day moving average of $11.02. The company has a current ratio of 27.91, a quick ratio of 27.91 and a debt-to-equity ratio of 0.05.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The firm had revenue of $55.10 million during the quarter, compared to the consensus estimate of $30.72 million. During the same quarter in the prior year, the firm earned ($0.38) EPS. Roivant Sciences’s revenue for the quarter was up 155.1% on a year-over-year basis. On average, research analysts forecast that Roivant Sciences will post -1.14 earnings per share for the current year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.